Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 2Phase 4 1Phase 3 1

Status

Completed 29Terminated 15Active not recruiting 12Recruiting 11Unknown 10Withdrawn 5Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Recurrence 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × pomalidomide × Clear all
NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT03841565 2022-06-15

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Academic and Community Cancer Research United

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT04584307 2021-08-23

Immuno-POWER

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT03227432 2018-08-14

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

University of Arkansas

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡